Background: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are commonly used diabetes and obesity medications but have been associated with gastrointestinal (GI) adverse events. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.